Literature DB >> 30637647

Nano-multilamellar lipid vesicles (NMVs) enhance protective antibody responses against Shiga toxin (Stx2a) produced by enterohemorrhagic Escherichia coli strains (EHEC).

M J Rodrigues-Jesus1, W L Fotoran2, R M Cardoso3, K Araki3, G Wunderlich2, Luís C S Ferreira4.   

Abstract

Microlipid vesicles (MLV) have a broad spectrum of applications for the delivery of molecules, ranging from chemical compounds to proteins, in both in vitro and in vivo conditions. In the present study, we developed a new set of nanosize multilayer lipid vesicles (NMVs) containing a unique combination of lipids. The NMVs enable the adsorption of histidine-tagged proteins at the vesicle surface and were demonstrated to be suitable for the in vivo delivery of antigens. The NMVs contained a combination of neutral (DOPC) and anionic (DPPG) lipids in the inner membrane and an external layer composed of DOPC, cholesterol, and a nickel-containing lipid (DGS-NTA [Ni]). NMVs combined with a recombinant form of the B subunit of the Shiga toxin (rStx2B) produced by certain enterohemorragic Escherichia coli (EHEC) strains enhanced the immunogenicity of the antigen after parenteral administration to mice. Mice immunized with rStx2B-loaded NMVs elicited serum antibodies capable of neutralizing the toxic activities of the native toxin; this result was demonstrated both in vitro and in vivo. Taken together, these results demonstrated that the proposed NMVs represent an alternative for the delivery of antigens, including recombinant proteins, generated in different expression systems.

Entities:  

Keywords:  Delivery system; Lipids vesicles; Multilamellar vesicles; Nanoparticles; Shiga toxin

Mesh:

Substances:

Year:  2018        PMID: 30637647      PMCID: PMC6863297          DOI: 10.1007/s42770-018-0035-0

Source DB:  PubMed          Journal:  Braz J Microbiol        ISSN: 1517-8382            Impact factor:   2.476


  49 in total

1.  Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2.

Authors:  Michael J Smith; Louise D Teel; Humberto M Carvalho; Angela R Melton-Celsa; Alison D O'Brien
Journal:  Vaccine       Date:  2006-03-03       Impact factor: 3.641

Review 2.  Molecular mechanisms of calcium-induced membrane fusion.

Authors:  D Papahadjopoulos; S Nir; N Düzgünes
Journal:  J Bioenerg Biomembr       Date:  1990-04       Impact factor: 2.945

Review 3.  Liposome-based delivery system for vaccine candidates: constructing an effective formulation.

Authors:  Ashwini Kumar Giddam; Ashwin Kumar Giddam; Mehfuz Zaman; Mariusz Skwarczynski; Istvan Toth
Journal:  Nanomedicine (Lond)       Date:  2012-12       Impact factor: 5.307

4.  Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli.

Authors:  Robert L G Rojas; Priscila A D P Gomes; Leticia V Bentancor; Maria E Sbrogio-Almeida; Sérgio O P Costa; Liliana M Massis; Rita C C Ferreira; Marina S Palermo; Luís C S Ferreira
Journal:  Clin Vaccine Immunol       Date:  2010-02-10

5.  Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.

Authors:  Jean Mukherjee; Kerry Chios; Dianne Fishwild; Deborah Hudson; Susan O'Donnell; Stephen M Rich; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

6.  Isolation of B subunit-specific monoclonal antibody clones that strongly neutralize the toxicity of Shiga toxin 2.

Authors:  Hideyuki Arimitsu; Keiko Sasaki; Yoshitaka Iba; Yoshikazu Kurosawa; Toshiyasu Shimizu; Takao Tsuji
Journal:  Microbiol Immunol       Date:  2015-02       Impact factor: 1.955

7.  Liposomes loaded with P. falciparum merozoite-derived proteins are highly immunogenic and produce invasion-inhibiting and anti-toxin antibodies.

Authors:  Wesley L Fotoran; Rachele M Santangelo; Márcia M Medeiros; Marcelle Colhone; Pietro Ciancaglini; Renato Barboza; Claudio Romero Farias Marinho; Rodrigo Guerino Stábeli; Gerhard Wunderlich
Journal:  J Control Release       Date:  2015-08-31       Impact factor: 9.776

8.  Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination.

Authors:  Sharmila Pejawar-Gaddy; James M Kovacs; Dan H Barouch; Bing Chen; Darrell J Irvine
Journal:  Bioconjug Chem       Date:  2014-07-14       Impact factor: 4.774

9.  DNA-Loaded Cationic Liposomes Efficiently Function as a Vaccine against Malarial Proteins.

Authors:  Wesley L Fotoran; Rachele Santangelo; Beatriz N M de Miranda; Darrell J Irvine; Gerhard Wunderlich
Journal:  Mol Ther Methods Clin Dev       Date:  2017-08-23       Impact factor: 6.698

10.  Development of DNA vaccines against hemolytic-uremic syndrome in a murine model.

Authors:  Alejandra V E Capozzo; Virginia Pistone Creydt; Graciela Dran; Gabriela Fernández; Sonia Gómez; Leticia V Bentancor; Carolina Rubel; Cristina Ibarra; Martín Isturiz; Marina S Palermo
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

View more
  5 in total

Review 1.  Prophylactic vaccine delivery systems against epidemic infectious diseases.

Authors:  Chao Pan; Hua Yue; Li Zhu; Guang-Hui Ma; Heng-Liang Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-07-17       Impact factor: 17.873

2.  Modeling Native EHEC Outer Membrane Vesicles by Creating Synthetic Surrogates.

Authors:  Alexander Kehl; Ronja Kuhn; Johanna Detzner; Daniel Steil; Johannes Müthing; Helge Karch; Alexander Mellmann
Journal:  Microorganisms       Date:  2020-05-06

3.  Nano-multilamellar lipid vesicles promote the induction of SARS-CoV-2 immune responses by a protein-based vaccine formulation.

Authors:  Monica Josiane Rodrigues-Jesus; Marianna Teixeira de Pinho Favaro; Aléxia Adrianne Venceslau-Carvalho; Maria Fernanda de Castro-Amarante; Bianca da Silva Almeida; Mariângela de Oliveira Silva; Robert Andreata-Santos; Cecilia Gomes Barbosa; Samantha Carvalho Maia Brito; Lucio H Freitas-Junior; Silvia Beatriz Boscardin; Luís Carlos de Souza Ferreira
Journal:  Nanomedicine       Date:  2022-08-27       Impact factor: 6.096

4.  Genomic Analysis of Shiga Toxin-Producing E. coli O157 Cattle and Clinical Isolates from Alberta, Canada.

Authors:  Emmanuel W Bumunang; Rahat Zaheer; Kim Stanford; Chad Laing; Dongyan Niu; Le Luo Guan; Linda Chui; Gillian A M Tarr; Tim A McAllister
Journal:  Toxins (Basel)       Date:  2022-08-31       Impact factor: 5.075

Review 5.  Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-Producing Escherichia coli.

Authors:  Su-Bin Hwang; Ramachandran Chelliah; Ji Eun Kang; Momna Rubab; Eric Banan-MwineDaliri; Fazle Elahi; Deog-Hwan Oh
Journal:  Front Cell Infect Microbiol       Date:  2021-06-29       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.